Meeting
2022 ASCO Annual Meeting
A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS).
Authors
Evan Rosenbaum
Memorial Sloan Kettering Cancer Center, New York, NY
Evan Rosenbaum , Li-Xuan Qin , Katherine Anne Thornton , Sujana Movva , Benjamin Alexander Nacev , Mark Andrew Dickson , Mrinal M. Gounder , Mary Louise Keohan , Viswatej Avutu , Ping Chi , Ciara Marie Kelly , Jason Earl Chan , Moriah Martindale , Travis Adamson , Olivia Robin McKennan , Joseph Patrick Erinjeri , Robert A Lefkowitz , William D. Tap , Sandra P. D'Angelo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04577014
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11516)
DOI
10.1200/JCO.2022.40.16_suppl.11516
Abstract #
11516
Poster Bd #
421
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2021 ASCO Annual Meeting
Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).
First Author: Steven Attia
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
First Author: Victor Manuel Villalobos
Poster
2015 ASCO Annual Meeting
Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies.
First Author: Andrew Eugene Hendifar